We assessed whether baseline plasma NTA-tau levels are useful in predicting longitudinal tau-PET increases, brain atrophy and cognitive decline in participants within the AD continuum (CU+ , MCI+ , AD+) at baseline (description in Supplementary Table 11–15, respectively). This evidence concerns the gene MAPT and Alzheimer disease.